文献速递前列腺癌

多参数磁共振成像可独立预测根治性前列腺切除术后挽救性放疗结局

Multiparametric Magnetic Resonance Imaging Is an Independent Predictor of Salvage Radiotherapy Outcomes After Radical Prostatectomy.
PubMed 文献 · Eur Urol · 2017-11-28

该回顾性研究纳入2003-2012年在本机构行根治性前列腺切除术后生化复发、并在挽救性放疗前12个月内接受多参数盆腔磁共振成像的473例患者,评估mpMRI对sXRT成功的预测价值。结果显示,在放疗前PSA≤0.5ng/ml的患者中,mpMRI阴性者4年PSA复发率(39% vs 12%,p<0.01)和转移率(16% vs 2%,p<0.01)反而更高,且mpMRI加入Stephenson列线图变量可提高预测PSA复发和转移的c-statistic。

要点

  • sXRT前mpMRI可独立预测PSA复发和转移,尤其在早期sXRT(PSA≤0.5ng/ml)患者中。
  • PSA≤0.5ng/ml患者中,mpMRI阴性者4年PSA复发39% vs 阳性者12%,转移16% vs 2%。
  • mpMRI加入列线图变量后,PSA复发c-statistic从0.71升至0.77,转移从0.66升至0.77。

核心结论

  • sXRT前mpMRI可改善临床病理变量对sXRT成功的预测,尤其在早期sXRT设置中。

研究设计与样本

  • 回顾性研究,纳入2003-2012年在本机构行根治性前列腺切除术后生化复发、并在sXRT前12个月内接受mpMRI的473例患者。

主要发现

  • 473例sXRT患者中,57%(204例)mpMRI显示病灶:26%(124例)膀胱尿道、28%(135例)精囊床/前列腺窝、7%(34例)淋巴结、1%(3例)骨。
  • 有病灶者mpMRI时中位PSA为0.46ng/ml,无病灶者为0.40ng/ml。
  • 排除淋巴结/骨病灶后,29%患者出现PSA复发,14%出现转移(sXRT后中位随访45个月)。
  • 放疗前PSA≤0.5ng/ml患者中,mpMRI阴性者4年PSA复发率39% vs 阳性者12%(p<0.01),转移率16% vs 2%(p<0.01)。
  • 放疗前PSA≤0.5ng/ml患者中,mpMRI加入倾向评分后,PSA复发c-statistic从0.71升至0.77(HR 3.60,p<0.01),转移从0.66升至0.77(HR 6.68,p<0.01)。

关键数值与推荐

  • mpMRI按二分类比较:无病灶 vs 膀胱尿道/精囊床/前列腺窝病灶。
  • 多变量Cox回归校正Stephenson列线图协变量。

临床怎么用

  • sXRT前mpMRI可用于改善对sXRT成功的预测,尤其在早期sXRT(PSA≤0.5ng/ml)患者中。

局限性

  • MRI技术演变。
  • 缺乏选择不接受sXRT而接受mpMRI的男性队列。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Stephenson nomogram is widely used to estimate the success of salvage radiotherapy (sXRT) for prostate cancer (PCa) recurrence after radical prostatectomy (RP). OBJECTIVE: To determine whether multiparametric pelvic magnetic resonance imaging (mpMRI) performed for biochemical recurrence after RP improves prognostication of sXRT relative to the Stephenson nomogram. DESIGN, SETTING, AND PARTICIPANTS: Men undergoing RP at our institution from 2003 to 2012 who had biochemical recurrence evaluated by mpMRI within 12 mo of sXRT were retrospectively reviewed. Exclusion criteria included PCa treatment prior to RP, adjuvant XRT after RP, salvage cryotherapy before sXRT, and hormone refractory disease prior to sXRT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable Cox regression analyses (adjusting for Stephenson nomogram covariates) associated mpMRI findings with prostate-specific antigen (PSA) recurrence and metastasis after sXRT. The mpMR images were compared in a binary fashion: no lesion versus vesicourethral/seminal vesical bed/prostate fossa lesions. RESULTS AND LIMITATIONS: Among 473 sXRT patients, 57%(204) had lesions on mpMRI: 26%(124) vesicourethral, 28%(135) seminal vesical bed/prostatic fossa, 7%(34) nodal, and 1%(3) bone. Median PSA at mpMRI with lesions was 0.46 versus 0.40ng/ml without lesions. After excluding nodal/bone lesions, 29% of men developed PSA recurrence and 14% metastasis (median follow-up 45 mo after sXRT). For patients with a pre-sXRT PSA of ≤0.5ng/ml, negative mpMRI was associated with increased PSA recurrence (39% vs 12%, p<0.01) and metastasis (16% vs 2%, p<0.01) at 4 yr after sXRT. For patients with a PSA of ≤0.5ng/ml, the addition of mpMRI to the propensity score (created using variables from the original Stephenson nomogram) improved the c-statistic from 0.71 to 0.77 for PSA recurrence (hazard ratio [HR] 3.60, p<0.01) and from 0.66 to 0.77 for metastasis (HR 6.68, p<0.01). Limitations include evolutions in MRI technique and lack of a cohort of men undergoing mpMRI electing against sXRT. CONCLUSIONS: Pre-sXRT mpMRI improves clinicopathologic variables to estimate sXRT success, particularly in the early sXRT setting. PATIENT SUMMARY: Men who have biochemically recurrent prostate cancer after radical prostatectomy often receive salvage radiotherapy. In our study, multiparametric pelvic magnetic resonance imaging prior to salvage radiotherapy was a significant predictor of prostate-specific antigen failure and metastasis after radiotherapy.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Sharma V, Nehra A, Colicchia M, et al. Multiparametric Magnetic Resonance Imaging Is an Independent Predictor of Salvage Radiotherapy Outcomes After Radical Prostatectomy. Eur Urol. 2017. PMID: 29195777. doi:10.1016/j.eururo.2017.11.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。